anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A comprehensive understanding of the cardio-spleen-bone marrow immune cell axis is essential for elucidating the alterations occurring during the pathogenesis of diabetes mellitus (DM). This study investigates the dynamics of immune cell kinetics in DM after myocardial infarction (MI) over time. MI was induced in diabetic and healthy control groups using C57BL/N6 mice, with sacrifices occurring at days 1, 3, 7, and 28 post-MI to collect heart, peripheral blood (PB), spleen, and bone marrow (BM) samples. Cell suspensions from each organ were isolated and analyzed via flow cytometry. Additionally, the endothelial progenitor cell-colony-forming assay (EPC-CFA) was performed using mononuclear cells derived from BM, PB, and the spleen. The results indicated that, despite normal production in BM and the spleen, CD45+ cells were lower in the PB of DM mice at days 1 to 3. Further analysis revealed a reduction in total and pro-inflammatory neutrophils (N1s) in PB at days 1 to 3 and in the spleen at days 3 to 7 in DM mice, suggesting that DM-induced alterations in splenic neutrophils fail to meet the demand in PB and ischemic tissues. Infiltrating macrophages (total, M1, M2) were reduced at day 3 in the DM-ischemic heart, with total and M1 (days 1-3) and M2 (days 3-7) macrophages being significantly decreased in DM-PB compared to controls, indicating impaired macrophage recruitment and polarization in DM. Myeloid dendritic cells (mDCs) in the heart were higher from days 1 to 7, which corresponded with the enhanced recruitment of CD8+ cells from days 1 to 28 in the DM-infarcted myocardium. Total CD4+ cells decreased in DM-PB at days 1 to 3, suggesting a delayed adaptive immune response to MI. B cells were reduced in PB at days 1 to 3, in myocardium at day 3, and in the spleen at day 7, indicating compromised mobilization from BM. EPC-CFA results showed a marked decrease in definitive EPC colonies in the spleen and BM from days 1 to 28 in DM mice compared to controls in vitro, highlighting that DM severely impairs EPC colony-forming activity by limiting the differentiation of EPCs from primitive to definitive forms. Taking together, this study underscores significant disruptions in the cardio-spleen-bone marrow immune cell axis following MI in DM, revealing delayed innate and adaptive immune responses along with impaired EPC differentiation.
The present invention relates to a traditional Chinese medicinal preparation for treating dermatosis, which belongs to the technical field of a Chinese patent medicine. The traditional Chinese medicinal preparation is prepared from a No. 1 lotion preparation and a No. 2 ointment preparation, wherein the No. 1 lotion preparation is composed of the following components according to the proportion by weight: 100 to 200 g of dry aloe leaf, 10 to 15g of saffron crocus, 500g of alcohol with a concentration of 75% to 80%; the No. 2 ointment preparation is composed of the following components according to the proportion by weight: 500 to 600g of stearic acid, 500 to 600g of glycerol, 40 to 60g of cholesterol, 30 to 50g of oxytetracycline, 10 to 30g of potassium hydroxide, 0.03 to 0.04g of aetylsalicylic acid, 30 to 60g of talcum powder, 10 to 30g of alum, 0.05 to 0.10g of sulfur, 0.8 to 1.2g of rosin, and 100g of purified water. The traditional Chinese medicinal preparation can treat obstinacy psoriasis, tinea of the feet and the hands, tinea circinata, tinea capitis, acne, viral fungal dermatosis, hypersensitive dermatosis, neurodermatitis, seborrheic dermatitis, eczema, urticaria and skin pruritus caused by various reasons, etc. and has the advantages of short course of treatment, rapid effect, no recurrence and no toxic side effect.
Background: Focused Assessment with Sonography in Trauma (FAST) examination is a point-of-care ultrasound study used to evaluate for abdominal hemorrhage, pneumothorax, or pericardial blood in trauma patients as an adjunct to their initial assessment. The quality of the image can be limited, and its diagnostic value is heavily dependent on operator skill. Our objective was to determine whether a standardized review process improved image quality and reduced incidence of nondiagnostic or insufficient imaging by 10% over a 6-month period. Study Design: Between July 1, 2021, and March 31, 2022, we evaluated 1106 trauma activations at our level II trauma center. Two exams per practitioner per month were reviewed by an emergency medicine trained traumatologist with specialized training in point-of-care ultrasound and board certification in echocardiography. Priority was given to exams on patients with known injuries identified on other studies. If there were no exams that matched these criteria, random exams were selected. Images were reviewed for image quality, diagnostic accuracy, and labeling with counseling given to the provider if indicated. Categorical variables were compared using chi squared analysis, while continuous non-normally distributed variables were compared using the Mann-Whitney U test. Results: A total of 305 FAST exams were reviewed (186 pre-intervention and 119 during intervention). Image quality improved from 46.3% (n = 31/65) to 79.0% (n = 94/119) (P < .01) with need for counseling falling from 63.1% (n = 41/65) pre-QI to 42.0% (n = 50/119) post-QI (P < .01). Incidence of detectable injury, BMI, ISS, and AIS body regions were consistent across the study period. This was seen in both the geriatric and non-geriatric cohorts despite a significant increase in ISS in the post-intervention geriatric patients.Discussion: A FAST review program is associated with improvement in image quality and decreased need for counseling of trauma providers.
The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a "Go4Life Workout to go" sample exercise routing created by the national institutes on aging (NIA).
This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult male and female volunteers A total of 23 subjects (16 males and 7 females) completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 24-hour blood draw. Subjects returned for all subsequent blood draws. Doses were separated by a washout period of 10 days.

Of the 24 healthy adult male and female volunteers enrolled in the study, 23 subjects (16 males and 7 females) completed the clinical phase of the study. Subject No. 10 failed to return for Period 2 check-in.
OBJECTIVE: The IKZF4(Ikaros family zinc finger 4) gene encodes Eos, a zinc finger transcription factor that belongs to the Ikaros family. High expression of Eos on Treg cells is important for the suppression of autoimmune responses and immune homeostasis. It has been suggested that the SNP in IKZF4 may influence the pathogenesis of AA(alopecia areata). The purpose of this study was to explore the relationship between IKZF4 polymorphism and AA in the Chinese Han population.
METHODS: We examined 459 patients and 434 controls in this study. The rs1701704 polymorphism was evaluated using HRM analysis and direct sequencing.
RESULTS: The prevalence of the C/C, A/C, and A/A genotypes in AA patients was 7.4%, 37.5% and 55.1%, respectively. There were significant differences in genotype distribution and allele frequencies between AA and the control group (P < .0001). The frequency of the C allele in the AA group was significantly higher (P < .0001), and the frequencies of the C allele and C/C genotype in patients with family history were higher (P < .0001; P = .001).
CONCLUSIONS: The rs1701704 SNP of IKZF4 may be a genetic marker for assessing the risk of AA in the Chinese Han population.
Constipation is directly related to the intestinal microenvironment, in which the promotion of gastrointestinal (GI) motility and improvement of gut microbiota distribution are important for alleviating symptoms. Herein, after the intervention of probiotic fermented milk (FMMIX) containing Lacticaseibacillus paracasei JY062 and Lactobacillus gasseri JM1 for 14 d in Kunming mice with loperamide-induced constipation, the results indicated that FMMIX significantly increased the secretion of serum motilin, gastrin and 5-hydroxytryptamine, as well as decreased the secretion of peptide YY, vasoactive intestinal peptide, and nitric oxide in mice. As determined by immunohistochemical analysis, FMMIX promoted an augmentation in the quantity of Cajal interstitial cells. In addition, the mRNA and protein expression of c-kit and stem cell factor (SCF) were upregulated to facilitate intestinal motility. High-throughput sequencing and gas chromatography techniques revealed that FMMIX led to an increase in the relative abundance of beneficial bacteria (Lactobacillus, Oscillospira, Ruminococcus, Coprococcus, and Akkermansia), reduced the presence of harmful bacteria (Prevotella), and resulted in elevated levels of short-chain fatty acids (SCFA) with a superior improvement compared with unfermented milk. Untargeted metabolomics revealed significant upregulation of functional metabolites such as l-pipecolinic acid, dl-phenylalanine, and naringenin in FMMIX, presumably playing a potential role in constipation relief. Overall, our results showed that FMMIX had the potential to alleviate constipation symptoms in mice by improving the secretion of serum GI regulatory peptides and neurotransmitters, increasing the expression of c-kit and SCF proteins, and modulating the gut microbiota structure and SCFA levels, and may be associated with an increase in these functional metabolites. This suggested that FMMIX could be a promising adjunctive strategy for managing constipation symptoms and could contribute to the development of functional foods aimed at improving gut health.
PURPOSE: To provide the subject preparation markedly greater in percutaneous permeation rate, excellent in medicinal stability, with mitigated skin irritancy, and also excellent in physical properties. CONSTITUTION: This preparation contains as active ingredient pref. 0.1-10 (esp. 1.0-5.0)wt.% of ketotifen acetate. This preparation is pref. a non-aqueous-based one, and its formulation is pref. plaster or ointment. This preparation is not subjected to metabolism by a medicine due to its initial passing effect through the liver observed following its oral administration, can secure sustained effective blood levels, and also avoid side effects of digestive system and various other side effects which may be developed in association with the rise in its rapid blood levels.  The formation of this preparation is e.g. a plaster with the tack layer composed of 0.1-10wt.% of the active ingredient and a base comprising 0.1-99wt.% of a liposoluble polymer, 0.1-70wt.% of a tackifier, 1.0-70wt.% of a softening agent and 0.01-20wt.% of an absorption promoter, or an ointment with the base containing a hydrocarbon, fatty acid ester, wax, surfactant and/or absorption promoter.
Participants will start on guanfacine-ER 1mg nightly for 1-week (week 1) and slowly increase by 1mg/per week to a max dose of 4mg per day or maximum dose as tolerated. Medication taper to discontinuation will begin in week 11 and continue into week 12 until complete by end of study, decreasing the dose by 1mg every 4 days until stopped.
The proposed study seeks to develop an effective, resource-sensitive strategy to manage weight loss treatment for obesity. During the 12-week active intervention phase, participants will be randomized to one of two first-line treatments: 1) mobile app alone (APP) or 2) app plus weekly telephone coaching sessions (APP+C). Beginning at week 2, those who are identified as treatment non-responders (did not lose an average of 0.5 lbs/week) will be re-randomized to one of two augmentation tactics: 1) Modest Step-up, operationalized as the addition of an additional mHealth component, or 2) Vigorous Step-up, operationalized as the addition of an additional mHealth component plus a traditional weight loss intervention component. Treatment responders will continue with the same first-line treatment. Treatment response be re-assessed at weeks 4 and 8. Those identified as treatment non-responders will be re-randomized at that time.
Patients attend 13 nutrition counseling sessions over 45 minutes each for 1 year. Patients may receive nutrition handouts.
The invention discloses an oil-in-water type antihypertensive drug of enalapril and safflower oil nanoemulsion. The materials and the weight percentages of the materials are as follows: 1-20% of the enalapril, 15-35% of surfactant, 0-20% of cosurfactant, 1-25% of the safflower oil, and the balance of distilled water. The sum of the weight percentages of the materials is 100%. The nanoemulsion has the advantages of small emulsion droplet particles, uniform distribution, small viscosity and good flowability. With the adoption of the dosage form of the nanoemulsion, water-soluble enalapril and fat-soluble safflower oil are organically combined, so that the dissolving and penetrating abilities of the safflower oil are improved, and the stability and the pesticide effect of the enalapril are increased. The advantages of the enalapril and the safflower oil are combined after the enalapril and the safflower oil are prepared into nanoemulsion formulation, so that the antihypertensive effect is obviously increased, the half-life period of the drug is prolonged and the administration times are also reduced.
An apparatus for performing a plurality of operation steps of a dialysis process is disclosed. The apparatus comprises a process controller for controlling the apparatus to perform the operation steps of the dialysis process, monitor process progress of the dialysis process and monitor sensor inputs of sensors of the apparatus; and a user interface, comprising a display, an input device and a user interface, UI, controller, wherein the UI controller is connected to enable presentation of graphical data on the display, and wherein the UI controller is connected to enable user interaction with the graphical data and connected to exchange information with the process controller, wherein the information is based on the user interaction of the user interface and monitoring of process progress of the dialysis process and sensor inputs of sensors of the apparatus by the process controller. Each of the operation steps are classified as one of a sequential operation step, which is dependent on completion of another operation step, and a non-sequential operation step, which is independent of completion of another operation step. The UI controller is configured to represent each of the operation steps by an operation step item which is a graphical item suitable to be presented on said display. The UI controller is configured to dynamically, for each of the operation steps, control enabling and disabling of interaction with the corresponding operation step items based on a state of respective operation step, wherein a completed state is assigned to each operation step that is completed, a non-completed state is assigned to each operation step that is non-completed, a selectable state is assigned to each operation step item of an operation step that is non-sequential and each operation step item of an operation step that is sequential but only in relation to a completed operation step, and a non-selectable state is assigned to each operation step item of an operation step that is sequential in relation to a non-completed operation step. A method and computer program are also disclosed.
Dental care chewing gum comprises silver. An independent claim is also included for preparing the dental care chewing gum, comprising: mixing the powdery and liquid ingredients, preferably in a cone mixer; kneading the mixture to homogeneity, preferably at a final temperature of 45[deg] C; subjecting the mixture to extrusion; and packing. ACTIVITY : Antibacterial. The antibacterial activity of the silver containing dental care chewing gum was tested based on the relative number of bacteria developing in the oral cavity after the initial administration, normal state and after the lunch. The result showed that the silver containing chewing gum consumed group exhibited a bacterial count of 98, where as the placebo group (chewing gum without silver) exhibited a count of 104. MECHANISM OF ACTION : None given.
A non-toxic preparation having immunomodulating activity and stimulating cytokine (interferons, tumor necrosis factor and others) formation is manufactured by extracting plants and plant residues and is suitable for therapeutic and preventive use in humans and animals. From the extract, preferably from peat extract, humic substances are eliminated by means of acidification with hydrochloric acid to pH 1,5 - 3,0 and separation. The extract is then concentrated by evaporation under reduced pressure and/or by means of nano-filtration with simultaneous elimination of inorganic salts. Next, the pH of the concentrated solution is brought to 6,0 - 7,1. The resulting mixture is then concentrated to a thick syrup and heated up to 70-90 °C until completion of Amadori rearrangement reaction of the products resulting from the reaction of simple sugars, oligo- and polysaccharides with amino acids and/or peptides extracted from peat. The reaction is then stopped by cooling and freed from hydrophobic substances - which would reduce the immunotropic activity of the product - by selective adsorption on a specific resin. The product thus obtained is converted into a sterile solid form by spray-drying.
PROBLEM TO BE SOLVED: To obtain an excellent antioxidant by forming a beet/sugarcane antioxidant composition which has specified physicochemical properties such as elemental analysis values, mol.wt., m.p., organic content, solubility in solvents, color reaction, discrimination among basicity, acidity and neutrality, color, shape, antioxidant properties and ultraviolet-absorbing capability. SOLUTION: This composition has such physicochemical properties that the elemental analysis values of C, H and N are 47.8%, 6.3% and 9.8%, respectively; the mol.wt. is 500-50,000; the m.p. is 300 deg.C or higher; it does not change even at 300 deg.C or higher; the organic content is 90-95%; it is completely soluble in water, easily soluble in an aqueous 50% ethanol solution, hardly soluble in an aqueous 75% ethanol solution and insoluble in ethanol; it has such color reactions that the ninhydrin reaction is + and the phenol-sulfuric acid reaction is +; its 1% aqueous solution is brown and clear; it has a pH of 5.0-6.5; it is a brown powder; and it exhibits strong antioxidant properties and ultraviolet absorption capability. This composition is prepared by removing low-mol.-wt. substances from a waste liquid separated in the chromatography step of a beet/cane sugar production plant.
The mechanisms of tissue damage in kidney amyloidosis are not well described. To investigate this further, we used laser microdissection-mass spectrometry to identify proteins deposited in amyloid plaques (expanded proteome) and proteins overexpressed in plaques compared to controls (plaque-specific proteome). This study encompassed 2650 cases of amyloidosis due to light chain (AL), heavy chain (AH), leukocyte chemotactic factor-2-type (ALECT2), secondary (AA), fibrinogen (AFib), apo AIV (AApoAIV), apo CII (AApoCII) and 14 normal/disease controls. We found that AFib, AA, and AApoCII have the most distinct proteomes predominantly driven by increased complement pathway proteins. Clustering of cases based on the expanded proteome identified two ALECT2 and seven AL subtypes. The main differences within the AL and ALECT2 subtypes were driven by complement proteins and, for AL only, 14-3-3 family proteins (a family of structurally similar phospho-binding proteins that regulate major cellular functions) widely implicated in kidney tissue dysfunction. The kidney AL plaque-specific proteome consisted of 24 proteins, including those implicated in kidney damage (α1 antitrypsin and heat shock protein β1). Hierarchical clustering of AL cases based on their plaque-specific proteome identified four clusters, of which one was associated with improved kidney survival and was characterized by higher overall proteomic content and 14-3-3 proteins but lower levels of light chains and most signature proteins. Thus, our results suggest that there is significant heterogeneity across and within amyloid types, driven predominantly by complement proteins, and that the plaque protein burden does not correlate with amyloid toxicity.
This study aimed to reveal the relationship between eating behavior and nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic liver disease (MASLD) in young adults and suggest a questionnaire for eating behavior assessment. We included 322 male graduate students at Gifu University. Diagnoses of NAFLD and MASLD were based on the presence of hepatic steatosis on ultrasonography. Eating behavior was assessed using the eating behavior questionnaire (EBQ) recommended by the Japan Society for the Study of Obesity. We assessed the eating behaviors associated with NAFLD and MASLD using logistic regression, decision tree, and random forest analyses. The median age of the participants was 22 years, and 16% and 11% had NAFLD and MASLD, respectively. The EBQ total score was significantly higher in participants with MASLD than in those without MASLD (102 vs. 90 points, P = 0.006) and in those with NAFLD than in those without NAFLD (97 vs. 90 points, P = 0.007). Among eating behavior categories, the decision tree and random forest analyses revealed that "perception of constitution and weight" was the strongest contributor for NAFLD/MASLD. Our study revealed that eating behavior assessed with the EBQ is robustly associated with NAFLD and MASLD in young male adults.
The Aurora A kinase has been shown to play an important role in neuroblastoma growth. Inhibition of Aurora A kinase activity attenuates the growth of neuroblastoma cells. MLN8237 is a selective small molecule inhibitor of Aurora A kinase that has completed pediatric single-agent phase I testing, as well as stage 1 phase 2 testing in patients with Neuroblastoma. MLN8237 showed activity against the NCI-sponsored Pediatric Preclinical Testing Program neuroblastoma in vivo panel that exceeded the activity level observed with chemotherapy agents routinely used in the treatment of neuroblastoma. Additional in vitro and in vivo studies have shown that Aurora A kinase inhibitors result in enhanced cytotoxicity when used in combination with chemotherapy. Irinotecan and temozolomide is a commonly used salvage regimen for patients with relapsed or refractory neuroblastoma. This combination has a modest objective response rate (16%) and is well-tolerated, suggesting that it will provide a useful platform for the study of novel compounds in combination with chemotherapy. Preclinical studies demonstrate marked enhancement of anti-neuroblastoma activity with the addition of MLN8237 to irinotecan and temozolomide. This study therefore evaluates the tolerability and activity of MLN8237 in combination with irinotecan and temozolomide in children with refractory or relapsed neuroblastoma. Patients receive irinotecan (50 mg/m2/dose IV) and temozolomide (100 mg/m2/dose orally) once daily for 5 days along with MLN8237 orally once daily for 7 days. The doses of irinotecan and temozolomide will be fixed and the dose of MLN8237 will be dose-escalated. In the phase I portion of the study, the primary aims are to determine the recommended phase II doses of this combination, describe the toxicity of this combination, and characterize the pharmacokinetic profile of MLN8237 and irinotecan when used in combination. In the phase II portion of the study, the primary aim is to determine the objective response rate of this combination in patients with relapsed or refractory neuroblastoma. With Amendment 5, the tolerability and pharmacokinetics of an MLN8237 oral solution will be evaluated. Optional correlative studies will evaluate UGT1A1 polymorphisms as predictors of toxicity and archival tumor tissue Aurora A expression as a predictor of response with this combination.